Cowen Healthcare Investments — 2024 Investments

1 investments dated 2024 · listed companies and verified rows first · show all

Torl Biotorlbio.comApr 2024

TORL BioTherapeutics develops antibody-drug conjugates (ADCs) targeting Claudin 6 (CLDN6) for the treatment of solid tumors such as ovarian, lung, endometrial, and testicular cancers.

BiotechHealthtechCulver City, US

Dave LicatainAran Maree M.D.inMark Alles(Executive Officer, Director)Mark Attanasio(Director)David Licata(Executive Officer, Director)Neil O'Brien(Director)

Co-investorsOCV Partners RA Capital Goldman Sachs Perceptive Xontogeny Venture Vertex Ventures HC

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.